Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Preterm Birth and PROM Testing Market, By Test

7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030

7.1.1. Ultrasound

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Biochemical Markers

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Pelvic Exam

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Nitazine Test

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. Uterine Monitoring

7.1.5.1. Market Revenue and Forecast (2017-2030)

7.1.6. Pooling

7.1.6.1. Market Revenue and Forecast (2017-2030)

7.1.7. Ferning Test

7.1.7.1. Market Revenue and Forecast (2017-2030)

7.1.8. Others

7.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Preterm Birth and PROM Testing Market, By End User

8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030

8.1.1. Diagnostic Laboratories

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Hospitals

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)

Chapter 10. Company Profiles

10.1. Abbott

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. Qiagen N.V.

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Biosynex

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. Hologic

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. Cooper Surgical

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Sera Prognostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. Medixbiochemica

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. IQ Products

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

10.9. NX Prenatal, Inc.

10.9.1. Company Overview

10.9.2. Product Offerings

10.9.3. Financial Performance

10.9.4. Recent Initiatives

10.10. Clinical Innovations, Inc.

10.10.1. Company Overview

10.10.2. Product Offerings

10.10.3. Financial Performance

10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms